 Kian Behbakht
Concepts (439)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 40 | 2024 | 386 | 5.340 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 6 | 2023 | 68 | 1.240 |
Why?
| | Endometrial Neoplasms | 10 | 2019 | 141 | 1.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2020 | 1356 | 1.050 |
Why?
| | Drug Resistance, Neoplasm | 15 | 2023 | 636 | 1.020 |
Why?
| | Genital Neoplasms, Female | 6 | 2020 | 70 | 0.960 |
Why?
| | Uterine Cervical Neoplasms | 8 | 2017 | 213 | 0.960 |
Why?
| | Peritoneal Neoplasms | 6 | 2022 | 54 | 0.950 |
Why?
| | Antineoplastic Agents | 10 | 2023 | 1875 | 0.800 |
Why?
| | Hysterectomy | 4 | 2018 | 105 | 0.780 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 5 | 2017 | 40 | 0.680 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1032 | 0.670 |
Why?
| | Cystadenocarcinoma, Serous | 5 | 2022 | 43 | 0.660 |
Why?
| | Gelatin | 2 | 2016 | 36 | 0.630 |
Why?
| | Neoplasms, Glandular and Epithelial | 3 | 2015 | 34 | 0.610 |
Why?
| | Thrombin | 2 | 2016 | 129 | 0.600 |
Why?
| | Models, Economic | 1 | 2018 | 48 | 0.600 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 66 | 0.590 |
Why?
| | Female | 79 | 2024 | 59325 | 0.540 |
Why?
| | Homeodomain Proteins | 3 | 2012 | 463 | 0.540 |
Why?
| | Pelvic Infection | 1 | 2016 | 4 | 0.530 |
Why?
| | Tissue Adhesives | 1 | 2016 | 16 | 0.530 |
Why?
| | Fallopian Tube Neoplasms | 5 | 2019 | 14 | 0.510 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 544 | 0.500 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2017 | 57 | 0.500 |
Why?
| | Cell Line, Tumor | 18 | 2023 | 2698 | 0.490 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2019 | 850 | 0.490 |
Why?
| | Women | 1 | 2015 | 51 | 0.470 |
Why?
| | Sirolimus | 2 | 2016 | 181 | 0.460 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2015 | 1168 | 0.410 |
Why?
| | Middle Aged | 46 | 2020 | 26605 | 0.410 |
Why?
| | Vagina | 5 | 2016 | 146 | 0.400 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 30 | 0.390 |
Why?
| | Cisplatin | 2 | 2015 | 262 | 0.390 |
Why?
| | Humans | 83 | 2024 | 114043 | 0.390 |
Why?
| | Aged | 34 | 2020 | 18969 | 0.350 |
Why?
| | Neoadjuvant Therapy | 4 | 2020 | 305 | 0.350 |
Why?
| | Neoplasm Staging | 14 | 2019 | 1162 | 0.350 |
Why?
| | Claudin-4 | 3 | 2022 | 9 | 0.350 |
Why?
| | Robotic Surgical Procedures | 3 | 2016 | 86 | 0.340 |
Why?
| | Uterine Neoplasms | 4 | 2019 | 73 | 0.340 |
Why?
| | Aged, 80 and over | 17 | 2020 | 6306 | 0.340 |
Why?
| | Apoptosis | 8 | 2019 | 2349 | 0.330 |
Why?
| | Pelvic Exenteration | 1 | 2009 | 11 | 0.330 |
Why?
| | Health Personnel | 1 | 2015 | 569 | 0.330 |
Why?
| | Leiomyosarcoma | 3 | 2020 | 26 | 0.330 |
Why?
| | Pyrimidines | 3 | 2019 | 374 | 0.330 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2020 | 39 | 0.330 |
Why?
| | Paclitaxel | 3 | 2019 | 190 | 0.330 |
Why?
| | Phthalazines | 2 | 2019 | 38 | 0.320 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 3 | 2017 | 26 | 0.320 |
Why?
| | Clinical Competence | 1 | 2015 | 882 | 0.310 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2020 | 332 | 0.300 |
Why?
| | Carcinoma, Endometrioid | 3 | 2019 | 46 | 0.300 |
Why?
| | Caffeine | 1 | 2008 | 56 | 0.300 |
Why?
| | Postoperative Complications | 6 | 2020 | 2122 | 0.300 |
Why?
| | Carbazoles | 1 | 2008 | 76 | 0.300 |
Why?
| | Azepines | 2 | 2019 | 69 | 0.300 |
Why?
| | Papanicolaou Test | 2 | 2004 | 39 | 0.280 |
Why?
| | Vaginal Smears | 2 | 2004 | 50 | 0.280 |
Why?
| | Piperazines | 2 | 2019 | 310 | 0.280 |
Why?
| | Adult | 29 | 2020 | 30375 | 0.280 |
Why?
| | Protein Kinase C | 1 | 2008 | 271 | 0.270 |
Why?
| | Hemostasis, Surgical | 2 | 2016 | 19 | 0.250 |
Why?
| | Adenocarcinoma | 4 | 2015 | 787 | 0.250 |
Why?
| | Laparotomy | 2 | 2015 | 101 | 0.240 |
Why?
| | Urban Health | 1 | 2004 | 73 | 0.240 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2020 | 1142 | 0.230 |
Why?
| | Disease-Free Survival | 7 | 2017 | 618 | 0.230 |
Why?
| | Fallopian Tubes | 1 | 2024 | 29 | 0.220 |
Why?
| | Pyrazoles | 2 | 2020 | 361 | 0.220 |
Why?
| | Genetic Therapy | 2 | 2014 | 256 | 0.220 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2003 | 42 | 0.200 |
Why?
| | Adenocarcinoma, Clear Cell | 2 | 2021 | 14 | 0.200 |
Why?
| | Leiomyoma | 2 | 2019 | 44 | 0.200 |
Why?
| | Healthcare Disparities | 2 | 2018 | 479 | 0.200 |
Why?
| | Prognosis | 8 | 2020 | 3315 | 0.190 |
Why?
| | Treatment Outcome | 11 | 2020 | 9049 | 0.190 |
Why?
| | Piperidines | 2 | 2019 | 159 | 0.190 |
Why?
| | Hospitals, Public | 1 | 2001 | 22 | 0.190 |
Why?
| | BRCA2 Protein | 3 | 2019 | 41 | 0.180 |
Why?
| | Mutation | 5 | 2019 | 3338 | 0.180 |
Why?
| | Neoplasms | 4 | 2017 | 2086 | 0.180 |
Why?
| | Hospitals, University | 1 | 2001 | 169 | 0.180 |
Why?
| | Vulvar Neoplasms | 1 | 2020 | 10 | 0.180 |
Why?
| | Cervix Uteri | 3 | 2011 | 44 | 0.180 |
Why?
| | Epoxy Compounds | 1 | 2020 | 31 | 0.170 |
Why?
| | Cell Movement | 2 | 2016 | 863 | 0.170 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 43 | 0.170 |
Why?
| | Enoxaparin | 1 | 2020 | 52 | 0.170 |
Why?
| | Rad51 Recombinase | 1 | 2019 | 14 | 0.170 |
Why?
| | Up-Regulation | 2 | 2020 | 802 | 0.170 |
Why?
| | Receptors, Adiponectin | 1 | 2019 | 15 | 0.170 |
Why?
| | Vaccines, Conjugate | 1 | 2019 | 59 | 0.160 |
Why?
| | Pyridones | 1 | 2020 | 122 | 0.160 |
Why?
| | Histocompatibility Antigens | 1 | 2019 | 98 | 0.160 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 87 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 675 | 0.160 |
Why?
| | Sequence Analysis, RNA | 2 | 2019 | 388 | 0.160 |
Why?
| | Interleukin-12 | 2 | 2014 | 110 | 0.160 |
Why?
| | Sarcoma | 1 | 2020 | 137 | 0.160 |
Why?
| | Breast Neoplasms | 4 | 2019 | 1846 | 0.160 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2019 | 96 | 0.150 |
Why?
| | Lymph Node Excision | 2 | 2020 | 140 | 0.150 |
Why?
| | Cancer Vaccines | 1 | 2019 | 137 | 0.150 |
Why?
| | Ovariectomy | 2 | 2015 | 116 | 0.150 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 206 | 0.150 |
Why?
| | Cost Savings | 1 | 2018 | 74 | 0.150 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2002 | 285 | 0.150 |
Why?
| | Oncologists | 1 | 2018 | 30 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2008 | 1836 | 0.150 |
Why?
| | Cell Growth Processes | 2 | 2008 | 51 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 428 | 0.150 |
Why?
| | Neoplasm Grading | 4 | 2019 | 241 | 0.140 |
Why?
| | Aurora Kinase A | 1 | 2017 | 51 | 0.140 |
Why?
| | Survival Rate | 5 | 2020 | 1638 | 0.140 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 181 | 0.140 |
Why?
| | Leukocyte Common Antigens | 1 | 2017 | 75 | 0.140 |
Why?
| | Risk Factors | 6 | 2016 | 8614 | 0.140 |
Why?
| | beta Catenin | 1 | 2019 | 218 | 0.140 |
Why?
| | Fatty Acids | 1 | 2020 | 380 | 0.140 |
Why?
| | Anion Transport Proteins | 1 | 2017 | 8 | 0.140 |
Why?
| | Salpingectomy | 2 | 2015 | 13 | 0.140 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2017 | 31 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 230 | 0.140 |
Why?
| | Gestational Trophoblastic Disease | 1 | 2016 | 5 | 0.140 |
Why?
| | Keratins | 1 | 2017 | 176 | 0.140 |
Why?
| | Curettage | 1 | 2016 | 9 | 0.140 |
Why?
| | Minority Groups | 1 | 2018 | 223 | 0.140 |
Why?
| | Megestrol Acetate | 1 | 2016 | 2 | 0.130 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 29 | 0.130 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2017 | 60 | 0.130 |
Why?
| | Animals | 12 | 2020 | 31565 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1519 | 0.130 |
Why?
| | Neoplasms, Squamous Cell | 1 | 1996 | 4 | 0.130 |
Why?
| | Colony Count, Microbial | 1 | 2016 | 111 | 0.130 |
Why?
| | Anticoagulants | 1 | 2020 | 547 | 0.130 |
Why?
| | Standard of Care | 1 | 2016 | 62 | 0.130 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 28 | 0.130 |
Why?
| | Gynecology | 1 | 2018 | 163 | 0.130 |
Why?
| | Adenoviridae | 1 | 1996 | 184 | 0.130 |
Why?
| | Brachytherapy | 1 | 2016 | 100 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 347 | 0.130 |
Why?
| | Keratin-5 | 1 | 2015 | 46 | 0.120 |
Why?
| | Tretinoin | 1 | 1996 | 122 | 0.120 |
Why?
| | Chemoradiotherapy | 1 | 2016 | 187 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 924 | 0.120 |
Why?
| | Tamoxifen | 1 | 2016 | 190 | 0.120 |
Why?
| | Immunohistochemistry | 3 | 2016 | 1624 | 0.120 |
Why?
| | Combined Modality Therapy | 4 | 2020 | 1117 | 0.120 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 138 | 0.120 |
Why?
| | Immunotherapy | 1 | 2018 | 473 | 0.120 |
Why?
| | Surgeons | 1 | 2018 | 236 | 0.120 |
Why?
| | CA-125 Antigen | 2 | 2008 | 12 | 0.120 |
Why?
| | Abdominal Abscess | 1 | 2014 | 25 | 0.120 |
Why?
| | Young Adult | 5 | 2020 | 10444 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2017 | 441 | 0.110 |
Why?
| | Reoperation | 1 | 2016 | 513 | 0.110 |
Why?
| | Cytokines | 1 | 2002 | 1824 | 0.110 |
Why?
| | Mice, SCID | 2 | 2012 | 312 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 4 | 2020 | 813 | 0.110 |
Why?
| | Glycoproteins | 1 | 2015 | 304 | 0.110 |
Why?
| | Interpersonal Relations | 1 | 2017 | 338 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2018 | 572 | 0.110 |
Why?
| | Endometrium | 1 | 2014 | 60 | 0.110 |
Why?
| | Mice | 8 | 2020 | 14841 | 0.110 |
Why?
| | Models, Biological | 3 | 2019 | 1611 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2016 | 397 | 0.110 |
Why?
| | Transforming Growth Factor beta | 1 | 1996 | 445 | 0.110 |
Why?
| | Antigens, CD | 1 | 2015 | 440 | 0.110 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 18 | 0.110 |
Why?
| | Plasmids | 1 | 2014 | 343 | 0.110 |
Why?
| | Genes, Tumor Suppressor | 3 | 1998 | 77 | 0.110 |
Why?
| | RNA, Messenger | 2 | 2012 | 2550 | 0.100 |
Why?
| | Escherichia coli | 1 | 2016 | 723 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 327 | 0.100 |
Why?
| | Antibody Specificity | 1 | 2012 | 175 | 0.100 |
Why?
| | Cell Division | 2 | 2008 | 754 | 0.100 |
Why?
| | RNA, Small Interfering | 3 | 2020 | 534 | 0.100 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 180 | 0.090 |
Why?
| | Endocrine Gland Neoplasms | 1 | 2011 | 1 | 0.090 |
Why?
| | Drug Synergism | 2 | 2011 | 315 | 0.090 |
Why?
| | Cyclin D1 | 1 | 2011 | 61 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 600 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 41 | 0.090 |
Why?
| | Cell Proliferation | 4 | 2019 | 2173 | 0.090 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2011 | 61 | 0.090 |
Why?
| | DNA | 1 | 2017 | 1350 | 0.090 |
Why?
| | Peptides | 1 | 2015 | 848 | 0.090 |
Why?
| | Transfection | 2 | 2007 | 863 | 0.090 |
Why?
| | Cadherins | 1 | 2011 | 175 | 0.090 |
Why?
| | Inflammation | 1 | 2020 | 2464 | 0.090 |
Why?
| | Neoplasm Invasiveness | 3 | 2016 | 438 | 0.090 |
Why?
| | Adolescent | 5 | 2020 | 17800 | 0.080 |
Why?
| | Age Factors | 5 | 2016 | 2885 | 0.080 |
Why?
| | Lymphoma | 1 | 2011 | 176 | 0.080 |
Why?
| | Skin Transplantation | 1 | 2009 | 57 | 0.080 |
Why?
| | Anastomosis, Surgical | 1 | 2009 | 135 | 0.080 |
Why?
| | Cell Survival | 3 | 2017 | 1014 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2011 | 367 | 0.080 |
Why?
| | Papillomaviridae | 2 | 2002 | 101 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2011 | 359 | 0.080 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2008 | 28 | 0.080 |
Why?
| | G2 Phase | 1 | 2008 | 31 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2019 | 3003 | 0.080 |
Why?
| | Rectum | 1 | 2009 | 151 | 0.080 |
Why?
| | Radiation-Protective Agents | 1 | 2008 | 26 | 0.070 |
Why?
| | Models, Statistical | 1 | 2011 | 595 | 0.070 |
Why?
| | Heterografts | 2 | 2019 | 117 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 695 | 0.070 |
Why?
| | Genes, BRCA1 | 2 | 1998 | 31 | 0.070 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 76 | 0.070 |
Why?
| | Urinary Bladder | 1 | 2009 | 161 | 0.070 |
Why?
| | Microsatellite Instability | 2 | 2019 | 32 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2020 | 12521 | 0.070 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 341 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2019 | 445 | 0.070 |
Why?
| | Cysteine | 1 | 2008 | 171 | 0.070 |
Why?
| | Length of Stay | 3 | 2015 | 957 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2019 | 1656 | 0.070 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 44 | 0.070 |
Why?
| | PTEN Phosphohydrolase | 2 | 2019 | 140 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2020 | 4392 | 0.070 |
Why?
| | Signal Transduction | 4 | 2012 | 4501 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1078 | 0.070 |
Why?
| | United States | 5 | 2022 | 12137 | 0.070 |
Why?
| | Models, Animal | 1 | 2008 | 340 | 0.070 |
Why?
| | Adenosarcoma | 2 | 2005 | 2 | 0.060 |
Why?
| | Indazoles | 2 | 2019 | 57 | 0.060 |
Why?
| | Cell Cycle | 1 | 2008 | 541 | 0.060 |
Why?
| | Ovary | 1 | 2007 | 190 | 0.060 |
Why?
| | Disease Progression | 3 | 2019 | 2371 | 0.060 |
Why?
| | Colposcopy | 2 | 2003 | 15 | 0.060 |
Why?
| | Sexual Behavior | 1 | 2009 | 434 | 0.060 |
Why?
| | Intestinal Neoplasms | 1 | 2005 | 24 | 0.060 |
Why?
| | Neoplasm Proteins | 3 | 1998 | 385 | 0.060 |
Why?
| | Cell Count | 2 | 2015 | 303 | 0.060 |
Why?
| | Germ-Line Mutation | 2 | 1996 | 131 | 0.060 |
Why?
| | Ultraviolet Rays | 1 | 2008 | 363 | 0.060 |
Why?
| | Chicago | 1 | 2004 | 45 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 1996 | 845 | 0.060 |
Why?
| | Transcription Factors | 4 | 2011 | 1525 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2008 | 665 | 0.060 |
Why?
| | Antioxidants | 1 | 2008 | 529 | 0.060 |
Why?
| | Blood Loss, Surgical | 2 | 2015 | 82 | 0.060 |
Why?
| | Survival Analysis | 4 | 2020 | 1206 | 0.050 |
Why?
| | Polymerase Chain Reaction | 3 | 2002 | 990 | 0.050 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 16 | 0.050 |
Why?
| | Receptors, Estrogen | 2 | 2015 | 371 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2015 | 521 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 81 | 0.050 |
Why?
| | Women's Health | 1 | 2004 | 270 | 0.050 |
Why?
| | Risk Assessment | 3 | 2016 | 2958 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 14 | 0.050 |
Why?
| | Gardnerella vaginalis | 1 | 2002 | 2 | 0.050 |
Why?
| | Pregnancy | 3 | 2016 | 5499 | 0.050 |
Why?
| | Trichomonas vaginalis | 1 | 2002 | 7 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2016 | 328 | 0.050 |
Why?
| | Gene Expression | 1 | 2007 | 1417 | 0.050 |
Why?
| | Vaginal Neoplasms | 1 | 2001 | 11 | 0.050 |
Why?
| | Yeasts | 1 | 2002 | 49 | 0.050 |
Why?
| | Vaginal Diseases | 1 | 2001 | 17 | 0.050 |
Why?
| | Epithelial Cells | 1 | 2007 | 946 | 0.050 |
Why?
| | Databases, Factual | 2 | 2016 | 1125 | 0.050 |
Why?
| | Endometriosis | 1 | 2001 | 40 | 0.050 |
Why?
| | DNA, Neoplasm | 2 | 1998 | 155 | 0.050 |
Why?
| | Prospective Studies | 4 | 2016 | 6195 | 0.050 |
Why?
| | Vulvectomy | 1 | 2020 | 2 | 0.040 |
Why?
| | DNA Primers | 1 | 2002 | 508 | 0.040 |
Why?
| | Histiocytoma, Malignant Fibrous | 1 | 2020 | 4 | 0.040 |
Why?
| | Dermatofibrosarcoma | 1 | 2020 | 9 | 0.040 |
Why?
| | Alleles | 3 | 2017 | 789 | 0.040 |
Why?
| | DNA Repair | 1 | 2022 | 184 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2001 | 128 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 45 | 0.040 |
Why?
| | Liposarcoma | 1 | 2020 | 25 | 0.040 |
Why?
| | Medically Uninsured | 1 | 2001 | 122 | 0.040 |
Why?
| | Anoikis | 1 | 2020 | 31 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2019 | 1331 | 0.040 |
Why?
| | Interleukin-10 | 1 | 2002 | 293 | 0.040 |
Why?
| | Hemocyanins | 1 | 2019 | 55 | 0.040 |
Why?
| | Logistic Models | 1 | 2004 | 1829 | 0.040 |
Why?
| | DNA Damage | 1 | 2022 | 351 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2020 | 54 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 787 | 0.040 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2019 | 17 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 195 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 275 | 0.040 |
Why?
| | Radiotherapy | 1 | 2020 | 175 | 0.040 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2019 | 25 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2019 | 57 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 31 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 37 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 84 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 301 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 1998 | 15 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 97 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 145 | 0.040 |
Why?
| | Mitosis | 1 | 2019 | 164 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 171 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2019 | 170 | 0.040 |
Why?
| | Europe | 1 | 2019 | 332 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2002 | 673 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 146 | 0.040 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 1998 | 30 | 0.040 |
Why?
| | Image Cytometry | 1 | 2017 | 5 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2002 | 965 | 0.040 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 1997 | 16 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1080 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 300 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 917 | 0.030 |
Why?
| | Cell Differentiation | 2 | 2011 | 1695 | 0.030 |
Why?
| | Ganciclovir | 1 | 1996 | 48 | 0.030 |
Why?
| | Chromosome Deletion | 1 | 1997 | 94 | 0.030 |
Why?
| | Time Factors | 2 | 2019 | 6077 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 622 | 0.030 |
Why?
| | Hospitals, Private | 1 | 2016 | 11 | 0.030 |
Why?
| | Health Facility Size | 1 | 2016 | 12 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 344 | 0.030 |
Why?
| | Chorionic Gonadotropin | 1 | 2016 | 78 | 0.030 |
Why?
| | Cell Separation | 1 | 2017 | 290 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 19 | 0.030 |
Why?
| | Ifosfamide | 1 | 1996 | 32 | 0.030 |
Why?
| | Marriage | 1 | 2017 | 105 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 1996 | 133 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 48 | 0.030 |
Why?
| | Hospital Charges | 1 | 1996 | 39 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 102 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2017 | 222 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 258 | 0.030 |
Why?
| | Caspase 3 | 1 | 2016 | 234 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 549 | 0.030 |
Why?
| | Cystadenocarcinoma, Papillary | 1 | 1995 | 5 | 0.030 |
Why?
| | Carboplatin | 1 | 1996 | 135 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 556 | 0.030 |
Why?
| | DNA Mismatch Repair | 1 | 2015 | 37 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 62 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 10 | 0.030 |
Why?
| | Genes, p53 | 1 | 1995 | 61 | 0.030 |
Why?
| | Income | 1 | 2016 | 167 | 0.030 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 150 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 19 | 0.030 |
Why?
| | Histones | 1 | 2019 | 529 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1690 | 0.030 |
Why?
| | Female Urogenital Diseases | 1 | 2014 | 5 | 0.030 |
Why?
| | RNA Interference | 1 | 2016 | 431 | 0.030 |
Why?
| | Taxoids | 1 | 2015 | 93 | 0.030 |
Why?
| | Morbidity | 1 | 2015 | 277 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 1996 | 1422 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2015 | 120 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 131 | 0.030 |
Why?
| | Bevacizumab | 1 | 2015 | 114 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 714 | 0.030 |
Why?
| | Reference Values | 1 | 1996 | 739 | 0.030 |
Why?
| | Point Mutation | 1 | 1995 | 216 | 0.030 |
Why?
| | Blood Volume | 1 | 2014 | 57 | 0.030 |
Why?
| | Bleomycin | 1 | 1996 | 228 | 0.030 |
Why?
| | Infusions, Parenteral | 1 | 2014 | 36 | 0.030 |
Why?
| | Polyethyleneimine | 1 | 2014 | 18 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 89 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 243 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2015 | 138 | 0.030 |
Why?
| | Hemostatics | 1 | 2014 | 44 | 0.030 |
Why?
| | DNA, Viral | 1 | 1996 | 349 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 283 | 0.030 |
Why?
| | Drainage | 1 | 2014 | 145 | 0.030 |
Why?
| | Biomarkers | 1 | 2024 | 3397 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2015 | 319 | 0.030 |
Why?
| | Lipids | 1 | 2017 | 564 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2018 | 632 | 0.030 |
Why?
| | Urban Population | 1 | 2016 | 396 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 143 | 0.030 |
Why?
| | Preoperative Care | 1 | 2015 | 319 | 0.030 |
Why?
| | Patient Readmission | 1 | 2018 | 607 | 0.030 |
Why?
| | Ultrasonography | 1 | 2016 | 635 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 177 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1016 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2014 | 147 | 0.030 |
Why?
| | Rural Population | 1 | 2016 | 443 | 0.030 |
Why?
| | Polymorphism, Single-Stranded Conformational | 3 | 1998 | 25 | 0.030 |
Why?
| | Linear Models | 1 | 1994 | 768 | 0.030 |
Why?
| | Cholesterol | 1 | 2014 | 368 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 784 | 0.020 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2011 | 23 | 0.020 |
Why?
| | Analysis of Variance | 1 | 1994 | 1218 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 47 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1447 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2272 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2011 | 95 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2013 | 200 | 0.020 |
Why?
| | DNA Fragmentation | 1 | 2011 | 47 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 57 | 0.020 |
Why?
| | Hyperplasia | 1 | 2011 | 163 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2012 | 280 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 660 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2011 | 227 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 1880 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 725 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2011 | 167 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 2014 | 430 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2343 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 561 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 945 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 770 | 0.020 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 1 | 2008 | 10 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2008 | 134 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1143 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 743 | 0.020 |
Why?
| | Quality Improvement | 1 | 2015 | 944 | 0.020 |
Why?
| | Sulfonamides | 1 | 2011 | 444 | 0.020 |
Why?
| | Placebos | 1 | 2008 | 197 | 0.020 |
Why?
| | Mice, Hairless | 1 | 2008 | 74 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3498 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 4402 | 0.020 |
Why?
| | Chromosome Mapping | 2 | 1998 | 486 | 0.020 |
Why?
| | Molecular Sequence Data | 3 | 1996 | 2783 | 0.020 |
Why?
| | Genetic Markers | 2 | 1998 | 320 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2008 | 350 | 0.020 |
Why?
| | Frameshift Mutation | 2 | 1996 | 27 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 4883 | 0.020 |
Why?
| | Gene Deletion | 2 | 1998 | 356 | 0.020 |
Why?
| | Carcinosarcoma | 1 | 2005 | 17 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1471 | 0.020 |
Why?
| | Colorado | 1 | 2014 | 4090 | 0.010 |
Why?
| | DNA Mutational Analysis | 2 | 1996 | 373 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2537 | 0.010 |
Why?
| | Obesity | 1 | 2016 | 2505 | 0.010 |
Why?
| | Base Sequence | 2 | 1996 | 2114 | 0.010 |
Why?
| | Loss of Heterozygosity | 1 | 1998 | 40 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 1998 | 137 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 1996 | 21 | 0.010 |
Why?
| | Genes, Neoplasm | 1 | 1995 | 20 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 722 | 0.010 |
Why?
| | BRCA1 Protein | 1 | 1995 | 56 | 0.010 |
Why?
| | Age of Onset | 1 | 1996 | 444 | 0.010 |
Why?
| | Introns | 1 | 1995 | 227 | 0.010 |
Why?
| | Exons | 1 | 1995 | 301 | 0.010 |
Why?
| | Male | 1 | 2017 | 55396 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1995 | 1981 | 0.010 |
Why?
|
|
Behbakht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|